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Abstract
Background: Annexin I, one of the 20 members of the annexin family of calcium and phospholipid-
binding proteins, has been implicated in diverse biological processes including signal transduction,
mediation of apoptosis and immunosuppression. Previous studies have shown increased annexin I
expression in pancreatic and breast cancers, while it is absent in prostate and esophageal cancers.
Results: Data presented here show that annexin I mRNA and protein are undetectable in 10 out
of 12 B-cell lymphoma cell lines examined. Southern blot analysis indicates that the annexin I gene
is intact in B-cell lymphoma cell lines. Aberrant methylation was examined as a cause for lack of
annexin I expression by treating cells 5-Aza-2-deoxycytidine. Reexpression of annexin I was
observed after prolonged treatment with the demethylating agent indicating methylation may be
one of the mechanisms of annexin I silencing. Treatment of Raji and OMA-BL-1 cells with
lipopolysaccharide, an inflammation inducer, and with hydrogen peroxide, a promoter of oxidative
stress, also failed to induce annexin I expression. Annexin I expression was examined in primary
lymphoma tissues by immunohistochemistry and presence of annexin I in a subset of normal B-cells
and absence of annexin I expression in the lymphoma tissues were observed. These results show
that annexin I is expressed in normal B-cells, and its expression is lost in all primary B-cell
lymphomas and 10 of 12 B-cell lymphoma cell lines.
Conclusions: Our results suggest that, similar to prostate and esophageal cancers, annexin I may
be an endogenous suppressor of cancer development, and loss of annexin I may contribute to B-
cell lymphoma development.
Background
The Annexins comprise a family of 20 calcium- and phos-
pholipid-binding proteins. Expressed in organisms rang-
ing from molds and plants to mammals, this family of
proteins has proven evolutionarily conserved as well as
functionally diverse. Structurally, annexins consist of a 70
amino acid core domain and an N-terminal domain,
which is variable in both length and sequence, and
imparts upon the family its functional diversity. Annexin
I has been implicated to have a biological role in
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inhibition of phospholipase A2 [1], as a substrate for epi-
dermal growth factor receptor [2] and intracellular cal-
cium release [3], regulation of hepatocyte growth factor
receptor signaling [4], and membrane trafficking [5]. Sub-
stantial evidence suggests a role for annexin I in glucocor-
ticoid-induced immunosuppression [6,7] and MAPK/ERK
pathway [7,8]. Increased expression of intracellular
annexin I is seen in bronchial epithelial cells grown in the
presence of dexamethasone [9] and secreted annexin I
appears to be proteolytically degraded by the human neu-
trophil elastase to an inactive form [10,11].
Annexin I is a critical mediator of apoptosis [12-15].
While overexpression of annexin I has been observed in
pancreatic [16], breast and gastric cancers [17], reduced or
no expression of annexin I has been reported in prostate
and esophageal cancers [18-21]. Thus differential regula-
tion of annexin I in a tissue specific manner may be asso-
ciated with the development of cancers in these sites.
Absence of annexin II expression has been reported in two
B-cell lymphoma cell lines, Raji and OMA BL-1 [22].
While annexin II is closely related to annexin I in amino
acid identity, its cellular function is clearly different [9].
Both annexins I and II are upregulated in pancreatic carci-
noma [16], and recent reports have shown absence of
both annexins I and II in prostate carcinoma
[20,21,23,24]. Thus, it appears that both annexins I and II
may be coordinately regulated. In view of these observa-
tions, the expression of annexin I in human B-cell lym-
phomas and cell lines was investigated in this study.
Methods
Cell culture, drug treatment and reagents
The human B-cell lymphoma cell lines used in this study
are: progenitor B-cell lines (Nalm-6, REH, HPB-Null, PBE-
1), B-lymphoblast cell lines (WI-L2, TK-6, DW-10, DHL-
16), Burkitt's lymphoma cell lines (Raji, Ramos, OMA-BL-
1, Namalwa). TK-6 is a lymphoblast cell line that is heter-
ozygote for thymidine kinase. TK-6 is a derivative of the
WI-L2, a lymphoblast cell line. DW-10 and WI-L2 are EBV
transformed mature B-cell lines. PBE-1 and NALM-6 are
both precursor B cell acute lymphoblastic leukemia cell
lines. NALM-6 is an established cell line and PBE1 is a line
established short term from a patient with ALL at the Uni-
versity of Nebraska Medical Center [Please note that a
DNA fingerprint analysis [25] of over 500 lymphoma-
leukemia cell lines indicated that PBE-1 and NALM6 may
be identical]. DHL-16 is a follicular B-cell lymphoma cell
line [26]. Human adenoids were used as a source of nor-
mal B-cells, and contained >80% B-cells as determined by
cell sorting and flow cytometric analysis. In other experi-
ments, normal B-cells were isolated from PBL of a healthy
volunteer using the human B-cell isolation kit (Miltenyi
Biotec Inc., Auburn, CA) as per manufacturer's guidelines.
SW1116, HeLa and 293T cells were used as positive con-
trols in the indicated experiments. Cells were grown in a
growth medium consisting of Eagle's minimum essential
medium (GIBCO-BRL, Grand Island, N.Y.) supplemented
with 10% heat-inactivated fetal bovine serum, L-
glutamine (2 mM), penicillin (100 U/ml) and streptomy-
cin (100 µg/ml). All cell lines were determined to be myc-
oplasma-free by a PCR-based mycoplasma detection
assay. 5-aza-2'-deoxycytidine (deoxyC, Sigma Chemical
Co., St. Louis, MO) was freshly prepared in distilled water.
Raji and OMA BL-1 cells, growing in T25 flasks, were incu-
bated in one of the following: 3 µM or 6 µM deoxyC for 3
days or 6 days; 2.5 to 10 µg/mL lipopolysaccharide from
E. coli (Sigma) for 24 hours; or 100 µM H2O2 for 2 to 24
hours. Genomic DNA, total cellular RNA and protein were
extracted from cells using previously published proce-
dures [22,27].
Tissue sections
Formalin-fixed, paraffin-embedded tissues representing
normal tonsil (n = 2), diffuse large cell non-cleaved B-cell
lymphoma (n = 2), small lymphocytic B-cell lymphoma
(n = 2) and follicular mixed B-cell lymphoma (n = 2) were
generously made available for these studies by Dr. Dennis
Weisenburger, Department of Pathology and Microbiol-
ogy, University of Nebraska Medical Center, Omaha, NE.
Sequential serial sections prepared from these specimens
were used in immunohistochemical analysis.
Antibodies
Polyclonal rabbit anti-human annexin I antisera (α646)
was a gift from Dr. Blake Pepinsky (Biogen, Boston, MA.).
Polyclonal anti-human phosphoglycerate kinase (PGK)
antiserum (α35) was prepared as described previously
[28]. The mouse monoclonal anti-CD 20 antibody was
from Beckman/Coulter Inc. (Westbrook, MA).
Gel electrophoresis and immunoblotting
Protein extracts were prepared from cells using protein
lysis buffer containing; 50 mM Tris-HCl pH 7.5, 2.0 mM
PMSF, 5.0 mM iodoacetamide, 5.0 mM EDTA, 150 mM
NaCl, 0.5% NP-40, and 0.5% Mega-9. Protease inhibitors
were added just prior to use (leupeptin at 1 µg/ml and
pepstatin at 2 µg/ml). Total amounts of protein extracts
was quantitated using Bio-Rad protein assay (Pierce,
Rockford, IL). A total of 50 µg of protein from each extract
was separated on a 12% SDS-PAGE. After electrophoresis,
proteins were transferred to PVDF membrane (Millipore,
Bedford, MA). The membranes were blocked in 1X TTBS
with 7% powdered milk overnight at 4°C and then
probed for 1 hour with rabbit polyclonal anti-human
annexin I (α646) at 1:500 dilution and rabbit polyclonal
anti-human PGK (α35) at 1:1000 dilution. Anti-rabbit
HRP (Promega, Madison, WI) at a dilution of 1:5000 was
used for 1 hour at room temperature to detect antigen-BMC Cancer 2004, 4 http://www.biomedcentral.com/1471-2407/4/8
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antibody complexes. Membranes were developed using
ECL+ (Amersham Pharmecia Biotech, Arlington Heights,
IL). For quantitation of the immunoreactive band, the
blot was scanned on a laser densitometer (Molecular
Dynamics, Sunnyvale, CA).
RNA isolation and polymerase chain reaction analysis
Total RNA was isolated from the cell monolayers or tissue
samples using RNeasy mini kit (Qiagen Inc., Valencia,
CA) or by TRIzol method (GIBCO/BRL). Annexin I mes-
sage was characterized by PCR using the enhanced Avian
RT-PCR kit (Sigma). Total RNA (5 µg) was added to each
RT reaction using random nonamer primers. The cDNA
products were amplified using annexin I specific primers
to give a 522 bp product. The primers designed for ampli-
fication were:
Annexin I forward: 5'-GCAAGAAGGTAGAGATAAAG-3',
Annexin I reverse: 5'-ATCTCTCTTCAGTTCCTCTC-3'
For verification of the integrity of the RNA samples and as
a control in all the RT-PCR analyses, we examined the
expression of the α-tubulin gene. The primers A-tu1 (5'-
AAG AAA TCC AAG CTG GAG TTC-3') and A-tu2 (5'-GTT
GGT CTG GAA TTC TGT CAG-3'), specific for the α-tubu-
lin gene, generated a 300 bp PCR product corresponding
to the α-tubulin gene.
Southern blot analysis
Genomic DNA was isolated from Raji, HPB-null, Nalm-6
and HeLa cell lines, and subjected to restriction endonu-
clease digestion. Southern blot analysis [29] of genomic
DNA was performed using radiolabeled 522 bp annexin I
cDNA product from the PCR reaction as described above.
Immunohistochemistry
Standard methods were used to prepare sequential 8 µM
sections of paraffin-embedded tissues, which were
mounted on polylysine-coated glass slides. Tissues were
cleared and rehydrated with two 10-minute rinses in a
ready-to-use tissue deparaffinization solution (Biogenex
Inc. San Ramon, CA). Sections were then stained by the
immunoperoxidase method using the ready-to-use
Vectastain Quick kit (Vector Labs, Burlingame, CA). Pri-
mary antibodies used included rabbit polyclonal anti-
human annexin I antibody and mouse monoclonal anti-
human CD 20 antibody.
Results
Expression of annexin I in human B-cell lymphoma cell 
lines
Annexin I protein levels were measured by immunoblot
analysis in various B-cell lymphoma cells along with and
other cell lines known to express annexin I. A typical auto-
radiogram is shown in Figure 1a. Extracts made from ade-
noid cells (containing > 80% B-cells) were used as control
normal cells, and HeLa cell extracts were used as positive
controls. As expected HeLa cells (lane 1) expressed high
levels of annexin I, and adenoids (lane 13) expressed
annexin I, but at a much reduced level when compared to
HeLa cells. Annexin I protein was undetectable in any of
the progenitor B-cell lines (Nalm-6, REH, HPB-Null, PBE-
1) and Burkitt's lymphoma cell lines (Raji, Ramos, OMA-
BL-1, Namalwa). Among the B-lymphoblast cell lines
(WI-L2, TK-6, DW-10), only WI-L2 expressed annexin I,
while its derivative TK-6 did not express annexin I. Using
a different source of normal B-cells (obtained from PBL of
a healthy volunteer), we once again confirmed annexin I
expression in normal B-cells (lane 1, Figure 1b). In addi-
tion, we find significantly reduced expression of annexin I
in the Burkitt's lymphoma cell line Raji and the follicular
lymphoma cell line DHL-16, when compared to the nor-
mal B-cells as evidenced by the levels of PGK in the same
blot. The expression of 3-phosphoglycerate kinase (PGK,
Figure 1) included as an internal control on the blots was
seen in all the cell lines except the adenoids. Expression of
proliferating cell nuclear antigen and the 70 and 90 kDa
subunits of Ku autoantigen were unaffected in these cell
lines (data not shown), indicating a specific lack of expres-
sion of annexin I.
Annexin I is transcriptionally regulated in B-cell lymphoma 
cell lines
In view of the lack of annexin I protein expression in the
B-cell lymphoma cell lines (Figure 1), annexin I message
expression was examined by RT-PCR analysis (Figure 2).
RT-PCR analysis showed that annexin I message was
present in adenoids (lane 1) and absent in all of the B-cell
lymphoma cell lines. As expected, HeLa (lane 11), 293T
(lane 12) and SW1116 (lane 13) cells showed annexin I
message.
Annexin I gene was examined in selected cell lines by
Southern blot analysis (Figure 3). There was no alteration
in the annexin II genomic DNA as seen by no change in
the hybridization pattern after cleavage by restriction
enzymes, Xba I, Bam H1 and Apa I. These enzymes gener-
ated specific fragments which were identical in the Raji,
HPB-null and Nalm-6 cell lines when compared to HeLa
cells. Therefore, the down-regulation of annexin I expres-
sion in B-cell lymphoma cells is at the transcriptional
level.
Effect of gene demethylation on annexin I expression
Methylation of the CpG dinucleotide has been shown to
directly inhibit transcription or stabilize structural
changes in chromatin that prevent transcription. The
nucleotide analogue, deoxyC was used to inhibit DNA
methylation in Raji cells to measure reexpression ofBMC Cancer 2004, 4 http://www.biomedcentral.com/1471-2407/4/8
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annexin I protein. Exposure of Raji cells to either low (1
µM) or high (10 µM) deoxyC did not result in reexpres-
sion of annexin I protein after 3 days (lanes 3 and 4).
However, after 6 days of treatment with deoxyC, as a weak
protein band (lanes 5 and 6) that appeared at the position
of annexin I was observed. There was no difference in
annexin I reexpression at 1 µM or 10 µM deoxyC
concentrations.
Raji cell line response to LPS and H2O2
To determine if inflammatory stimulus provided by expo-
sure of cells to bacterial LPS will result in expression of
annexin I, Raji cells were treated with various concentra-
tions of LPS, and annexin I protein expression was meas-
ured by immunoblot analysis. The data in Figure 5 (panel
A) show that exposure of Raji cells to LPS does not result
in expression of annexin I in these cells. The effect of pro-
ducing reactive oxygen species (ROS) in Raji cells on
annexin I expression was also investigated. The data in
Figure 5 (panel B) show that exposure of Raji cells to H2O2
did not cause annexin I expression.
Expression of annexin I in human B-cell lymphoma cell lines Figure 1
Expression of annexin I in human B-cell lymphoma 
cell lines. Whole cell extracts were prepared from HeLa 
(lane 1), REH (lane 2), HPB-Null (lane 3), DW-10 (lane 4), 
Nalm-6 (lane 5), Namalwa (lane 6), PBE-1 (lane 7), Ramos 
(lane 8), Raji (lane 9), OMA-BL-1 (lane 10), WI-L2 (lane 11), 
TK-6 (lane 12) and adenoid (lane 13) in panel A and extracts 
prepared from normal B-cells obtained from PBL (lane 1), 
DHL-16 (lane 2) and Raji (lane 3) cells in panel B were used 
to measure expression of annexin I. Extracts equivalent to 20 
µg of protein were subjected to SDS-gel electrophoresis and 
immunoblotting as described in Materials and Methods. Pro-
tein blots were incubated with a 1:2000 dilution of polyclonal 
anti-annexin I (α646) antiserum and 1:500 dilution of anti-
human PGK antiserum (α35). Positions of the molecular 
weight markers, PGK and annexin I are indicated.
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B
RT-PCR analysis of annexin I expression in B-cell lymphoma  cell lines Figure 2
RT-PCR analysis of annexin I expression in B-cell 
lymphoma cell lines. Panel A shows mRNA expression of 
annexin I in B-cell lymphoma cell lines, adenoids, and positive 
control cell lines (HeLa, 293T and SW1116). Panel B shows a 
corresponding RT-PCR analysis of α-tubulin in the same cell 
lines. The cell lines shows in both panels are: adenoid (lane 
1), OMA-BL-1 (lane 2), Raji (lane 3), Ramos (lane 4), PBE-1 
(lane 5), Namalwa (lane 6), Nalm-6 (lane 7), DW-10 (lane 8), 
HPB-null (lane 9), REH (lane 10), HeLa (lane 11), 293T (lane 
12) and SW1116 (lane 13). The 100-bp ladder is shown in 
lane M.
Southern blot analysis Figure 3
Southern blot analysis. Genomic DNA from Raji, HPB-
null, Nalm-6 and HeLa cell lines was digested with XbaI (X), 
BamH1 (B) and ApaI (A), or left undigested (U) as indicated 
and Southern blot analysis was performed as described under 
Materials and Methods.
M   1    2    3     4    5    6    7    8    9   10  11   12  13 M
M   1    2    3     4    5    6    7    8    9   10  11   12  13 M
A
B
α-tubulin
Annexin I
1   2    3    4     5     6     7    8     9    10  11  12   13  14  15  16
U   X    B    A    U     X   B   A     U   X    B    A    U    X B   A
Raji HPB-null Nalm-6 HeLaBMC Cancer 2004, 4 http://www.biomedcentral.com/1471-2407/4/8
Page 5 of 8
(page number not for citation purposes)
Immunohistochemical analysis of annexin I expression in 
B-cell lymphoma
Annexin I expression was studied by immunohistochemi-
cal analysis on archival specimens representing various B-
cell lymphomas. Tonsil tissue sections were included as
representatives of normal tissue. Positive identification of
B-cells was performed by immunodetection of CD 20
antigen. As expected, CD 20 positivity was observed in the
germinal centers (Figure 6, panel A) and a few CD 20 pos-
itive cells were observed in the epithelial layer. Annexin I
expression was predominantly in the epithelial layer (Fig-
ure 6, panel B). Weakly positive annexin I expressing cells
were found within the germinal center. At higher magnifi-
cations (Figure 6, panels C and D), distinct cytoplasmic
localization of annexin I was observed in a subset of cells
within the germinal center (Figure 6, panel D). These
results are consistent with the immunoblot data (Figure
1) indicating a low-level of annexin I expression in the
adenoids.
Annexin I expression was absent in the B-cell lymphomas
(Figure 7). Distinct B-cell clusters were observed by their
CD 20 positivity in diffuse large cell non-cleaved B-cell
lymphoma (Figure 7, panel A), small lymphocytic B-cell
lymphoma (Figure 7, panel C) and follicular mixed B-cell
lymphoma (Figure 7, panel E). However annexin I expres-
sion was undetectable in each of these B-cell lymphomas
(Figure 7, panels B, D and F) even at higher magnifica-
Methylase inhibitor 5-aza-2'-deoxycytidine does not cause  reexpression of annexin I in Raji cells Figure 4
Methylase inhibitor 5-aza-2'-deoxycytidine does not 
cause reexpression of annexin I in Raji cells. Raji cells 
were cultured in the absence (lane 2) or presence of 1 µM 
(lanes 3 and 5) and 10 µM (lanes 4 and 6) of 5-aza-2'-deoxy-
cytidine for 3 (lanes 3 and 4) or 6 days (lanes 5 and 6). Pro-
tein extracts made from cells were subjected to Western 
blot analysis for annexin I and PGK as in Figure 1.
PGK
Annexin I
293T Raji
M      1       2        3        4        5       6
Treatment of Raji cells with LPS or H2O2 does not induce  annexin I Figure 5
Treatment of Raji cells with LPS or H2O2 does not 
induce annexin I. Raji cells were treated with 0 to 10 µg/
ml of LPS for 24 hours (Panel A) or with 100 µM H2O2 for 0 
to 24 hours (Panel B). Extracts made from cells were sub-
jected to SDS-PAGE and immunoblot analysis for annexin I 
and PGK as described under legend to Figure 1. 293T cells 
were included as positive control.
Immunohistochemical analysis of annexin I in normal tonsil Figure 6
Immunohistochemical analysis of annexin I in normal 
tonsil. Panel A: CD 20 staining of normal tonsil reveals clus-
ters of B-cells referred to as germinal centers. Panel B: 
Annexin I staining of the next serial section shows annexin I 
presence in tonsil epithelium with weak immunopositivity in 
the germinal centers. At higher magnifications (panels C and 
D), distinct cytoplasmic staining of annexin I is observed in a 
subset of cells (panel D) that represent the germinal center 
CD 20 positive cells (panel C). Magnification: 40× (panels A 
and B), 400× (panels C and D).
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tions (data not shown). Strong epithelial cell staining of
annexin I was observed in these specimens (Figure 7,
panel D). These results are consistent with the absence of
annexin I expression in B-cell lymphoma cell lines (Fig-
ures 1 and 2).
Discussion
In this study, the expression of annexin I in B-cell lym-
phoma was examined. Annexin I is a pleotrophic, calcium
and phospholipid binding protein whose proposed func-
tions include anti-inflammatory activity, mediation of
apoptosis, regulation of cell differentiation, and mem-
brane trafficking [8,15,30]. Annexin I is expressed in the
secretory bronchial epithelial cells [9] and its anti-inflam-
matory N-terminus is lost in the bronchoalveolar lavage
fluids from healthy smokers [11] indicating the impor-
tance of this protein in human health and disease.
Annexin I is frequently overexpressed in human cancers
including pancreatic [16] and breast [17] cancers. How-
ever, recent reports indicate that annexin I expression is
down-regulated in other human tumors, particularly
esophageal and prostate tumors [19-21]. Annexin I is sim-
ilar to the closely related protein annexin II, even though
the two proteins are proposed to carry out distinct physi-
ological functions. Curiously, both annexins I and II are
lost in prostate cancers [20,21,23,24]. Altered expression
and loss of annexin II in B-cell lymphoma cell lines has
been reported previously [22]. In view of this, the
expression of annexin I in B-cell lymphomas and cell lines
were examined in the present study.
The data presented in this manuscript indicate that
annexin I is present in normal B-cells (Figure 1, panels A
and B). Immunohistochemical examination of normal
tonsil sections (Figure 6) indicates that a subset of cells
within the germinal centers distinctly express annexin I.
The germinal center normally harbors highly proliferative
B-cells [31], however it also represents a highly dynamic
environment that creates intense genomic instability
among B-cells [32]. It is unclear if the subset of B-cells that
show annexin I expression represent proliferative cells or
cells that are undergoing differentiation. Association of
annexin I expression and cellular differentiation has been
shown previously [33].
In contrast, most cells lines and neoplasms of pregerminal
B-cells did not show detectable annexin I expression. Our
data are consistent with the loss of annexin I observed in
prostate and esophageal cancers [21]. The etiology of
reduced annexin I expression was studied by examining
the possible mechanisms. Southern blot analysis indi-
cated that annexin I gene was intact in the Raji and OMA-
BL1 cells, indicating that genomic deletion of annexin I is
not the cause for loss of annexin I. Gene silencing by
hypermethylation of annexin I promoter was examined
by culturing cells in the presence of a demethylating
agent, and the data indicated reexpression of annexin I
protein after prolonged exposure to 10 µM concentration
of deoxyC. Thus, methylation of annexin I promoter
could be one of the mechanisms for annexin I silencing in
these cells. These results are similar to the reexpression of
annexin II observed in a prostate cancer cell line after
treatment with deoxyC [23], indicating methylation as a
general mechanism for silencing annexins I and II in
Annexin I expression is undetectable in B-cell lymphomas Figure 7
Annexin I expression is undetectable in B-cell lym-
phomas. Panels A and B: CD 20 staining illustrates four 
localized clusters of B-cells (panel A). No Annexin I staining 
appears in the next serial section (panel B). Panels C and D: 
CD 20 positive B-cells appear in a defined cluster in this sec-
tion (panel C). Staining for Annexin I clearly indicates 
absence of the protein in this B-cell cluster (panel D). How-
ever, Annexin I staining does localize in the epithelial layer of 
the section. Panels E and F: CD 20 positive B-cells form large 
follicles that are characteristic of this type of lymphoma 
(panel E). Annexin I staining does not localize in these folli-
cles (panel F). Magnification: 40×.
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cancer tissues. Treatment of cells with a pro-inflammatory
agent or an apoptosis inducing agent did not result in
expression of annexin I.
Conclusion
The data presented in this paper show that the anti-
inflammatory protein annexin I is expressed in normal B-
cells, but not expressed in B-cell lymphomas and cell
lines, similar to the absence of annexin I in prostate and
esophageal cancers. Thus, annexin I may be an endog-
enous suppressor of cancer development, and loss of
annexin I may contribute to B-cell lymphoma develop-
ment. The additional mechanism(s) by which annexin I
expression is down-regulated and the physiological conse-
quences of annexin I loss in B-cell lymphomas need fur-
ther investigation.
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